← All Propanc Biopharma, INC filings

Propanc Biopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PPCB
Propanc Biopharma, INC
10-K: Propanc Biopharma Reports Soaring Losses Amid R&D Focus
Propanc Biopharma, a biopharmaceutical company, reported a significant increase in net loss to $58.9 million for fiscal year 2025, driven by substantial stock-based compensation, while advancing its lead cancer drug candidate, PRP, towards Phase Ib clinical trials.
NASDAQ
PPCB
Propanc Biopharma, INC
10-K: Propanc Biopharma Reports Fiscal Year 2024 Results, Outlines Clinical Trial Plans
Propanc Biopharma, a biopharmaceutical company focused on cancer treatments, released its fiscal year 2024 results and detailed its plans for upcoming clinical trials.